In SELECT-PsA 1, rates of any serious adverse event and hepatic disorder were higher with adalimumab, while anemia was higher with upadacitinib 15 mg, in patients with axial involvement compared to those without; serious infection and CPK elevation were higher with upadacitinib 15 mg versus adalimumab in patients without axial involvement compared to those with axial involvement (Table 2). Here, PIK3C2A is linked to infection.